HIV breakthrough? antibody cocktail aims to replace daily meds

NCT ID NCT05245292

Completed Disease control Sponsor: Rockefeller University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested whether a single infusion of two long-acting antibodies plus repeated injections of an immune-stimulating drug can keep HIV under control after people stop their daily antiretroviral therapy. Twenty-eight adults with well-controlled HIV participated. The goal was to see if the combination is safe and can delay or prevent the virus from rebounding.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: two broadly neutralizing antibodies (3BNC117-LS and 10-1074-LS) plus an IL-15 superagonist (N-803)
What this could lead to: If successful, this could point toward a way for people with HIV to stop daily antiretroviral therapy while keeping the virus under control.
What could go wrong: This is a very early, small Phase 1 trial with only 28 participants, so results may not apply widely. The treatment may not prevent viral rebound, and side effects from the antibodies or immune stimulant are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HUMAN IMMUNODEFICIENCY VIRUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AIDS HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HUMAN IMMUNODEFICIENCY VIRUS

Contacts and locations

Locations

Perelman School of Medicine University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States
The Rockefeller University

New York, New York, 10065, United States
Weill Cornell Medicine, Cornell Clinical Trials Unit

New York, New York, 10021, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.